NFL Biosciences: potential in smoking cessation confirmed

(CercleFinance.com) - NFL Biosciences experienced some profit-taking on Monday morning, despite the announcement of satisfactory results from its Phase 2 clinical trial in smoking cessation.


The biopharmaceutical company - which develops botanical medicines to combat dependency and addiction - reports that the potential of its NFL-101 has been confirmed, as the fundamental objectives of the study were met.

The trial demonstrated an effect that compared favorably with current treatments, with efficacy comparable to that of Champix, but without its side effects.

The company underlines that its NFL-101 confirms its disruptive potential by matching the efficacy of the best current treatment with just two administrations versus twice-daily dosing for twelve weeks,

The efficacy rates obtained in the study lead the company to envisage the start of a Phase 3 study.

Following these good results, the share - which has climbed 78% since the start of the year - nevertheless suffered some profit-taking, falling by 8%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.